Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Anticancer Substances Clear Next Hurdle

12.03.2013
Scientists of the MPI of Biochemistry and their cooperation partners of the Lead Discovery Center GmbH (LDC) have now signed a licensing agreement with the Korean company Qurient for a group of active substances that have been a focus of their research for a long time.

These substances shall target metastasizing and drug-resistant tumors more specifically and selectively. Qurient will successively enter the tested substances into preclinical and clinical trials in order to use them in the future for drugs. The Max Planck researchers hope that if the experiments and clinical trials are successful, a drug based on the new active substances could be on the market by the end of the decade.


To activate the Axl kinase and transmit its signal to the cell nucleus, a signal substance (blue) has to bind externally and the energy carrier ATP (green) internally. The inhibitors (orange) prevent a transmission of the signal by blocking the ATP binding site.
Picture: Axel Ullrich/Copyright: MPI of Biochemistry

According to the World Health Organization (WHO), cancer causes about 7.6 million deaths per year, making it the second leading cause of death in the world after cardiovascular disease. Most cancer patients die of the disease because tumor cells spread to other sites in the body and form new tumors, so-called metastases. Therefore, there is a growing need for effective drugs. The new substances, which are the research focus of the three cooperation partners, belong to the family of highly specific Axl kinase inhibitors. In the research department headed by Axel Ullrich at the MPI of Biochemistry, the scientists Pjotr Knyazev and Robert Torka have been conducting research on the protein Axl kinase and its inhibitors for more than ten years.

The Axl kinase is a receptor protein that is found on the surface of many cell types. It recognizes specific signal substances that play a critical role in the survival and migration of cells. The researchers showed that fewer metastases develop when the Axl kinase is inactivated. In many aggressive types of cancer the Axl kinase is present at too high levels and is thus hyperactive. For this reason, the cells are constantly stimulated to grow or migrate.

“If we block the Axl kinase, we can prevent the cancer cells from migrating and forming new metastases,” said Robert Torka, explaining the effect of the new substances. The target that the inhibitors attack is located in the interior of the cell, at the Axl kinase domain. After the appropriate signaling substance is bound externally, an energy carrier (ATP) must additionally dock to the receptor internally before the signal can be transmitted to the cell nucleus. The new substances prevent the ATP from binding and the receptor from becoming activated and thus prevent the signal from reaching the cell nucleus. All Axl kinase-dependent processes are therefore blocked in the cancer cell.

Various groups of such inhibitors have already been patented at the MPI of Biochemistry. To make the individual substances even more effective against particularly aggressive, metastasizing tumors, it was necessary to generate chemical variants. The Lead Discovery Center GmbH (LDC) assumed this part of the cooperation. For example, the LCD scientists altered the substances so that they were more soluble. The researchers at the MPI of Biochemistry then tested the variants on different cancer cell lines derived from the lung, breast or pancreas e.g. for tolerance, dosage or efficacy in combination with other active substances.

The Qurient Company will successively bring the substances to preclinical and clinical trials, in order to use them later as drugs. To continue to optimize the agents further, the scientists of the MPI of Biochemistry and the LDC are participating with tests and experiments for an additional year of collaboration. Afterwards both partners take over a consulting function during the whole development process. “Our common goal is to make tumor treatments more selective and targeted to the tumor cells. The new substances are a step in the right direction,” said Pjotr Knyazev, scientist in the Department of Molecular Biology at the MPI of Biochemistry. [VS]

Contact

Prof. Dr. Axel Ullrich
Molecular Biology
Max Planck Institute of Biochemistry
Am Klopferspitz 18
82152 Martinsried
Germany
e-mail: ullrich@biochem.mpg.de
www.biochem.mpg.de/ullrich
Anja Konschak
Public Relations
Max Planck Institute of Biochemistry
Am Klopferspitz 18
82152 Martinsried
Germany
Phone: +49 (0) 89 8578-2824
e-mail: konschak@biochem.mpg.de

Anja Konschak | Max-Planck-Institut
Further information:
http://www.biochem.mpg.de
http://www.biochem.mpg.de/en/news/pressroom/index.html

More articles from Life Sciences:

nachricht Fish recognize their prey by electric colors
13.11.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht The dawn of a new era for genebanks - molecular characterisation of an entire genebank collection
13.11.2018 | Leibniz-Institut für Pflanzengenetik und Kulturpflanzenforschung

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

Im Focus: Penn engineers develop ultrathin, ultralight 'nanocardboard'

When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure

Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...

Im Focus: Coping with errors in the quantum age

Physicists at ETH Zurich demonstrate how errors that occur during the manipulation of quantum system can be monitored and corrected on the fly

The field of quantum computation has seen tremendous progress in recent years. Bit by bit, quantum devices start to challenge conventional computers, at least...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

European Space Talks: Weltraumschrott – eine Gefahr für die Gesellschaft?

23.10.2018 | Event News

 
Latest News

The dawn of a new era for genebanks - molecular characterisation of an entire genebank collection

13.11.2018 | Life Sciences

Fish recognize their prey by electric colors

13.11.2018 | Life Sciences

Ultrasound Connects

13.11.2018 | Awards Funding

VideoLinks
Science & Research
Overview of more VideoLinks >>>